Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Plasma cell dependence on histone/protein deacetylase 11 reveals a therapeutic target in multiple myeloma

18 Nov 2021

Abstract excerpt

The clinical utility of histone/protein deacetylase (HDAC) inhibitors in combinatorial regimens with proteasome inhibitors for patients with relapsed and refractory multiple myeloma (MM) is often limited by excessive toxicity due to HDAC inhibitor promiscuity with multiple HDACs. Therefore, more selective inhibition minimizing off-target toxicity may increase the clinical effectiveness of HDAC inhibitors. We...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Histone Deacetylase Inhibitors Research
Share to Multiple Myeloma Research and Treatments
Share to Protein Degradation and Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34793338
DOI: 10.1172/jci.insight.151713

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 9 closest

Plasma cell dependence on histone/protein deacetylase 11 reveals a therapeutic target in multiple myelomaPMID 34793338Read ↗

Dysregulated Class I histone deacetylases are indicators of poor prognosis in multiple myelomaSemantic proximity Read ↗

Exploring the role of histone deacetylase and histone deacetylase inhibitors in the context of multiple myeloma: mechanisms, therapeutic implications, and future perspectivesSemantic proximity Read ↗

HDAC11 deficiency disrupts oncogene-induced hematopoiesis in myeloproliferative neoplasms.Semantic proximity Read ↗

Gene expression-based prediction of myeloma cell sensitivity to histone deacetylase inhibitorsSemantic proximity Read ↗

IMiDs prime myeloma cells for daratumumab-mediated cytotoxicity through loss of Ikaros and AiolosSemantic proximity Read ↗

Che-1/AATF-induced transcriptionally active chromatin promotes cell proliferation in multiple myelomaSemantic proximity Read ↗

HDAC11 is a novel drug target in carcinomasSemantic proximity Read ↗

HDAC inhibition by LBH589 affects the phenotype and function of human myeloid dendritic cells.Semantic proximity Read ↗

Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myelomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.